Has it been four weeks already?

As recently mentioned, the field of breast cancer research is nothing if not full of highly-powered, multicenter, seemingly decades-long trials. Which is good, since there are many questions that need answering.

Like this one: if aromatase inhibitors are better than tamoxifen at preventing recurrence in postmenopausal women, would the same hold true for premenopausal women in whom we induce menopause? Oh, if it were that simple.

As always, you can get the full-screen version here.